Achieving Quiescence with Fluocinolone Implants

Freia McGregor, Andrew D Dick, Tomas Burke

Research output: Contribution to journalArticle (Academic Journal)peer-review

1 Citation (Scopus)
18 Downloads (Pure)


Persistent anterior uveitis causing cystoid macular oedema may necessitate either intraocular or systemic immunosuppression. This case report highlights how a newly licenced treatment, fluocinolone acetonide (Iluvien®, Alimera Sciences Ltd., England, UK) achieves quiescence in refractory and steroid-dependent disease and in the presence of an acute relapse.

Original languageEnglish
Pages (from-to)356-362
Number of pages7
JournalCase reports in ophthalmology
Issue number2
Publication statusPublished - 10 May 2021

Bibliographical note

Funding Information:
Chris Wright, Senior Director Scientific Communications Alimera Sciences Limited ? review and funding for publication.-

Publisher Copyright:
© 2021


Dive into the research topics of 'Achieving Quiescence with Fluocinolone Implants'. Together they form a unique fingerprint.

Cite this